drugset
drugset / Trial / NCT03842982

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

NCT03842982 ↗

Phase 3 Active not recruiting 362 enrolled Centre Oscar Lambret
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.

Timeline

Start
2019-05-03
Primary completion
2031-02-01
Completion
2031-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Background Sodium Thiosulfate Diagnostic / imaging agent 12 g/kg Intravenous

Indications

ovarian carcinoma